NexImmune
Gaithersburg, US · Founded 2011 · Delaware corporation · 2 known investors
NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Founders & leadership
NexImmune was founded in 2011 by Jonathan Schneck.
JS
Jonathan SchneckFounder
AC
Alain CappelutiExecutive
KC
Kenneth CarterExecutive
Board
JN
Janis NaeveBoard director
JB
James BarrettBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$34.7M disclosed across 6 rounds · 2011–2019
▶$7.8MraisedFeb 2019 · 42 investors · BiotechnologyRule 506(b)
▶$7.8MraisedFeb 2019 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bing YaoDirector
- Paul D'AngioDirector
- Scott CarmerExecutive Officer, Director
- Timothy BertramDirector
- Alain CappelutiExecutive Officer
- Alan RoemerDirector
- Robert SpiegelDirector
- Tony YaoDirector
- Offering amount
- $10M
- Amount sold
- $7.8M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.7MraisedFeb 2018 · 69 investors · BiotechnologyRule 506(b)
▶$21.7MraisedFeb 2018 · 69 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott CarmerExecutive Officer, Director
- Bing YaoDirector
- Tony YaoDirector
- Alain CappelutiExecutive Officer
- Paul D'AngioDirector
- Timothy BertramDirector
- Robert SpiegelDirector
- Alan RoemerDirector
- Offering amount
- $25M
- Amount sold
- $21.7M
- Finders' fees
- $450K
- Placement agents
- Trout Capital LLC
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2015 · 4 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Janis NaeveDirector
- Jonathan SchneckDirector
- Alain CappelutiExecutive Officer, Director
- James BarrettDirector
- Kenneth CarterExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$3MraisedJul 2014 · 3 investors · BiotechnologyRule 506(b)
▶$3MraisedJul 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alain CappelutiExecutive Officer, Director
- Kenneth CarterExecutive Officer, Director
- Janis NaeveDirector
- James BarrettDirector
- Jonathan SchneckDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1KraisedFeb 2012 · 9 investors · BiotechnologyRule 506(b)
▶$1KraisedFeb 2012 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SchneckDirector
- Alain CappelutiExecutive Officer, Director
- Kenneth CarterExecutive Officer, Director
- Offering amount
- $1K
- Amount sold
- $1K
- First sale
- Jun 2011
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06
▶$287.5KraisedFeb 2012 · 11 investors · BiotechnologyRule 506(b)
▶$287.5KraisedFeb 2012 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth CarterExecutive Officer, Director
- Jonathan SchneckDirector
- Alain CappelutiExecutive Officer, Director
- Offering amount
- $287.5K
- Amount sold
- $287.5K
- First sale
- Nov 2011
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Immunome23 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Evommune22 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Primmune Therapeutics21 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Inimmune20 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Thymmune15 shared keywordsThymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.
Companies competing with NexImmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NexImmune do?
- NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
- Who founded NexImmune?
- NexImmune was founded by Jonathan Schneck in 2011.
- Who are NexImmune's investors?
- NexImmune's investors include Pfizer Venture Investments, Rapha Capital Management, LLC.
- How much funding has NexImmune raised?
- NexImmune has disclosed $34.7M raised across 6 rounds.
- Where is NexImmune headquartered?
- NexImmune is headquartered in Gaithersburg, US.